BRAF and metastatic melanoma: Currently, targeted therapies for metastatic melanoma mainly include BRAF and MEK inhibitors, such as Vemurafenib (the first FDA-approved BRAF inhibitor), dabrafenib, encorafenib, trametinib (the first FDA-approved MEK inhibitor), cobimetinib, and binimetinib (Shirley 2018).